David Lebwohl's most recent trade in Intellia Therapeutics Inc was a trade of 61,714 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 61,714 | 61,714 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,200 | 130,866 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 9,557 | 87,666 (0%) | 0% | 12.2 | 116,404 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 3,189 | 0 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 3,189 | 97,223 (0%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 55,855 | 55,855 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 38,701 | 93,073 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 5,843 | 54,372 (0%) | 0% | 29.5 | 172,135 | Common Stock |
| Intellia Therapeutics Inc | Lebwohl David | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,187 | 60,215 (0%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | Lebwohl David | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,187 | 3,189 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 43,342 | 43,342 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 30,674 | 56,361 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 2,574 | 25,687 (0%) | 0% | 37.2 | 95,779 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,187 | 6,376 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,187 | 28,261 (0%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 13,816 | 24,738 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 13,816 | 13,816 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,187 | 9,563 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,187 | 11,973 (0%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 112.24 per share. | 01 Jan 2022 | 1,051 | 10,922 (0%) | 0% | 112.2 | 117,964 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 2,400 | 180,077 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 05 Nov 2021 | 2,400 | 11,114 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 131.71 per share. | 05 Nov 2021 | 1,200 | 9,914 (0%) | 0% | 131.7 | 158,052 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 134.07 per share. | 05 Nov 2021 | 548 | 8,914 (0%) | 0% | 134.1 | 73,470 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 132.62 per share. | 05 Nov 2021 | 452 | 9,462 (0%) | 0% | 132.6 | 59,944 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 135.34 per share. | 05 Nov 2021 | 200 | 8,714 (0%) | 0% | 135.3 | 27,068 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2021 | 2,400 | 182,477 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 14 Oct 2021 | 2,400 | 11,114 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 127.81 per share. | 14 Oct 2021 | 849 | 9,714 (0%) | 0% | 127.8 | 108,511 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 126.92 per share. | 14 Oct 2021 | 551 | 10,563 (0%) | 0% | 126.9 | 69,933 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 129.83 per share. | 14 Oct 2021 | 525 | 8,964 (0%) | 0% | 129.8 | 68,161 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 130.47 per share. | 14 Oct 2021 | 250 | 8,714 (0%) | 0% | 130.5 | 32,618 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 129.01 per share. | 14 Oct 2021 | 225 | 9,489 (0%) | 0% | 129.0 | 29,027 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2021 | 7,923 | 184,877 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 24 Sep 2021 | 7,923 | 8,714 (0%) | 0% | 12.6 | 99,988 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 2,400 | 192,800 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 149.81 per share. | 21 Sep 2021 | 2,400 | 791 (0%) | 0% | 149.8 | 359,544 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 21 Sep 2021 | 2,400 | 3,191 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 30 Aug 2021 | 2,400 | 3,191 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 2,400 | 195,200 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 159.19 per share. | 30 Aug 2021 | 1,100 | 941 (0%) | 0% | 159.2 | 175,109 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 156.70 per share. | 30 Aug 2021 | 700 | 2,291 (0%) | 0% | 156.7 | 109,690 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 157.60 per share. | 30 Aug 2021 | 250 | 2,041 (0%) | 0% | 157.6 | 39,400 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 155.43 per share. | 30 Aug 2021 | 200 | 2,991 (0%) | 0% | 155.4 | 31,086 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 160.10 per share. | 30 Aug 2021 | 150 | 791 (0%) | 0% | 160.1 | 24,015 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 2,400 | 197,600 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 164.05 per share. | 09 Aug 2021 | 2,400 | 791 (0%) | 0% | 164.1 | 393,720 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 09 Aug 2021 | 2,400 | 3,191 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 76,500 | 76,500 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 12,750 | 12,750 | - | - | Restricted Stock Unit |